论文部分内容阅读
Ranitidine为一种类似甲氰咪胍(Cimetidine)的新药,近年来已引起很大重视。它用于治疗溃疡具有相当于甲氰咪胍的功效,而作用于肝脏酶类所引起的副作用却较小。目前,咪唑核类化合物被认为是主要的H_2-受体阻断剂。如今发现氨基烷基呋喃衍生物——Ranitidine(AH-19065),经体内试验其抑制胃分泌的作用较咪唑核类化合物强5～10倍。这一新药已由英国格兰索公司开发。经体内体外药理试验,均表明本品为一种具有选择性和竞争性的组织胺H_2-受体拮抗剂,而对H_1-受体无显著作用。本品用麻醉鼠灌注胃试验,静注抑制胃
Ranitidine, a new drug similar to Cimetidine, has drawn great attention in recent years. It is used to treat ulcers that have the equivalent of cimetidine, with fewer side effects caused by enzymes acting on the liver. Currently, imidazole nucleosides are considered as major H 2 -receptor blockers. It has now been found that the aminoalkylfuran derivative, Ranitidine (AH-19065), is 5 to 10 times more potent than the imidazole nucleosides in inhibiting gastric secretion in vivo. The new drug has been developed by the British company Granto. In vitro and in vivo pharmacological tests, all showed that this product is a selective and competitive histamine H 2 -receptor antagonist, H_1-receptor no significant effect. This product is anesthetized rats perfusion stomach test, intravenous inhibition of the stomach